XML 31 R20.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Operating Segments | 9 Months Ended
--- | ---
Sep. 30, 2018
Segment Reporting [Abstract] |
Operating Segments |
11. | Operating Segments
In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (a) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision makers (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available. Our reporting segments are defined as below: TREATMENT SEGMENT, which includes:
| – | nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through three uniquely licensed and permitted treatment and storage facilities; and
| – | research and development (“R&D”) activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.
SERVICES SEGMENT, which includes:
| – | Technical services, which include:
| ○ | professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;
| ○ | integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;
| ○ | global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and
| ○ | on-site waste management services to commercial and governmental customers.
| – | Nuclear services, which include:
| ○ | technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services, logistics, transportation, processing and disposal;
| ○ | remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; logistics; transportation; and emergency response; and
| – | A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.
MEDICAL SEGMENT reporting includes: R&D costs for the new medical isotope production technology from our majority-owned Polish subsidiary, PF Medical. The Medical Segment has not generated any revenue as it continues to be primarily in the R&D stage. All costs incurred for the Medical Segment are reflected within R&D in the accompanying Consolidated Statements of Operations. As previously disclosed, during 2016, the Medical Segment ceased a substantial portion of its R&D activities for the medical isotope production technology due to the need for substantial capital to fund such activities. The Company does not anticipate that the Medical Segment will restart such activities until it obtains such funding. Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 10 – Discontinued Operations”) which do not generate revenues. The table below presents certain financial information of our operating segments for the three and nine months ended September 30, 2018 and 2017 (in thousands). Segment Reporting for the Quarter Ended September 30, 2018
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 9,103 |  |  | $ | 2,881 |  |  |  | — |  |  | $ | 11,984 |  |  | $ | — |  |  | $ | 11,984 |
Intercompany revenues |  |  | 174 |  |  |  | 16 |  |  |  | — |  |  |  | 190 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 1,564 |  |  |  | 261 |  |  |  | — |  |  |  | 1,825 |  |  |  | — |  |  |  | 1,825 |
Research and development |  |  | 126 |  |  |  | — |  |  |  | 88 |  |  |  | 214 |  |  |  | 15 |  |  |  | 229 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 82 |  |  |  | 82 |
Interest expense |  |  | (8 | ) |  |  | (1 | ) |  |  | — |  |  |  | (9 | ) |  |  | (53 | ) |  |  | (62 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (10 | ) |  |  | (10 | )
Depreciation and amortization |  |  | 234 |  |  |  | 122 |  |  |  | — |  |  |  | 356 |  |  |  | 8 |  |  |  | 364 |
Segment income (loss) before income taxes |  |  | 506 |  |  |  | (224 | ) |  |  | (88 | ) |  |  | 194 |  |  |  | (1,219 | ) |  |  | (1,025 | )
Income tax (benefit) expense |  |  | (1,342) | (4) |  |  | — |  |  |  | — |  |  |  | (1,342 | ) |  |  | — |  |  |  | (1,342 | )
Segment income (loss) |  |  | 1,848 |  |  |  | (224 | ) |  |  | (88 | ) |  |  | 1,536 |  |  |  | (1,219 | ) |  |  | 317 |
Expenditures for segment assets |  |  | 525 |  |  |  | 22 |  |  |  | — |  |  |  | 547 |  |  |  | 1 |  |  |  | 548 |
Segment Reporting for the Quarter Ended September 30, 2017
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 9,355 |  |  | $ | 2,403 |  |  |  | — |  |  | $ | 11,758 |  |  | $ | — |  |  | $ | 11,758 |
Intercompany revenues |  |  | 77 |  |  |  | 10 |  |  |  | — |  |  |  | 87 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 1,613 |  |  |  | 132 |  |  |  | — |  |  |  | 1,745 |  |  |  | — |  |  |  | 1,745 |
Research and development |  |  | 96 |  |  |  | — |  |  |  | 197 |  |  |  | 293 |  |  |  | — |  |  |  | 293 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 34 |  |  |  | 34 |
Interest expense |  |  | (1 | ) |  |  | (1 | ) |  |  | — |  |  |  | (2 | ) |  |  | (57 | ) |  |  | (59 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9 | ) |  |  | (9 | )
Depreciation and amortization |  |  | 964 |  |  |  | 134 |  |  |  | — |  |  |  | 1,098 |  |  |  | 9 |  |  |  | 1,107 |
Segment income (loss) before income taxes |  |  | 40 | (2) |  |  | (478 | ) |  |  | (197 | ) |  |  | (635 | ) |  |  | (1,271 | ) |  |  | (1,906 | )
Income tax expense |  |  | 70 |  |  |  | — |  |  |  | — |  |  |  | 70 |  |  |  | 1 |  |  |  | 71 |
Segment (loss) income |  |  | (30 | ) |  |  | (478 | ) |  |  | (197 | ) |  |  | (705 | ) |  |  | (1,272 | ) |  |  | (1,977 | )
Expenditures for segment assets |  |  | 81 |  |  |  | 3 |  |  |  | — |  |  |  | 84 |  |  |  | — |  |  |  | 84 |
Segment Reporting for the Nine Months Ended September 30, 2018
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 27,207 |  |  | $ | 10,594 |  |  |  | — |  |  | $ | 37,801 |  |  | $ | — |  |  | $ | 37,801 |
Intercompany revenues |  |  | 463 |  |  |  | 55 |  |  |  | — |  |  |  | 518 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 5,867 |  |  |  | 1,322 |  |  |  | — |  |  |  | 7,189 |  |  |  | — |  |  |  | 7,189 |
Research and development |  |  | 355 |  |  |  | — |  |  |  | 259 |  |  |  | 614 |  |  |  | 66 |  |  |  | 680 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 212 |  |  |  | 212 |
Interest expense |  |  | (16 | ) |  |  | (2 | ) |  |  | — |  |  |  | (18 | ) |  |  | (159 | ) |  |  | (177 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (27 | ) |  |  | (27 | )
Depreciation and amortization |  |  | 702 |  |  |  | 367 |  |  |  | — |  |  |  | 1,069 |  |  |  | 26 |  |  |  | 1,095 |
Segment income (loss) before income taxes |  |  | 4,279 | (3) |  |  | (194 | ) |  |  | (259 | ) |  |  | 3,826 |  |  |  | (3,740 | ) |  |  | 86 |
Income tax (benefit) expense |  |  | (1,277) | (4) |  |  | — |  |  |  | — |  |  |  | (1,277 | ) |  |  | 5 |  |  |  | (1,272 | )
Segment income (loss) |  |  | 5,556 |  |  |  | (194 | ) |  |  | (259 | ) |  |  | 5,103 |  |  |  | (3,745 | ) |  |  | 1,358 |
Expenditures for segment assets |  |  | 1,016 |  |  |  | 82 |  |  |  | — |  |  |  | 1,098 |  |  |  | 4 |  |  |  | 1,102 |
Segment Reporting for the Nine Months Ended September 30, 2017
|  | Treatment |  |  | Services |  |  | Medical |  |  | Segments Total |  |  | Corporate (1) |  |  | Consolidated Total |
Revenue from external customers |  | $ | 29,019 |  |  | $ | 8,160 |  |  |  | — |  |  | $ | 37,179 |  |  | $ | — |  |  | $ | 37,179 |
Intercompany revenues |  |  | 191 |  |  |  | 21 |  |  |  | — |  |  |  | 212 |  |  |  | — |  |  |  | — |
Gross profit |  |  | 6,474 |  |  |  | 343 |  |  |  | — |  |  |  | 6,817 |  |  |  | — |  |  |  | 6,817 |
Research and development |  |  | 339 |  |  |  | — |  |  |  | 947 |  |  |  | 1,286 |  |  |  | 14 |  |  |  | 1,300 |
Interest income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 105 |  |  |  | 105 |
Interest expense |  |  | (27 | ) |  |  | (2 | ) |  |  | — |  |  |  | (29 | ) |  |  | (220 | ) |  |  | (249 | )
Interest expense-financing fees |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (27 | ) |  |  | (27 | )
Depreciation and amortization |  |  | 2,960 |  |  |  | 405 |  |  |  | — |  |  |  | 3,365 |  |  |  | 29 |  |  |  | 3,394 |
Segment income (loss) before income taxes |  |  | 2,880 | (2) |  |  | (1,738 | ) |  |  | (947 | ) |  |  | 195 |  |  |  | (3,855 | ) |  |  | (3,660 | )
Income tax expense |  |  | 215 |  |  |  | — |  |  |  | — |  |  |  | 215 |  |  |  | 3 |  |  |  | 218 |
Segment income (loss) |  |  | 2,665 |  |  |  | (1,738 | ) |  |  | (947 | ) |  |  | (20 | ) |  |  | (3,858 | ) |  |  | (3,878 | )
Expenditures for segment assets |  |  | 188 |  |  |  | 12 |  |  |  | — |  |  |  | 200 |  |  |  | — |  |  |  | 200 |
(1) Amounts reflect the activity for corporate headquarters not included in the segment information. (2) Amounts include tangible asset impairment loss of $672,000 for the Company’s M&EC subsidiary. (3) Amounts included a net gain of $1,596,000 recorded resulting from the exchange offer of the Series B Preferred Stock of our M&EC subsidiary (see “Note 13 – M&EC Series B Preferred Stock” below). (4) Amounts included a tax benefit recorded in the amount of approximately $1,380,000 during the third quarter. (see “Note 12 – Income Taxes” below).

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration